Osimertinib 80 mg Price in China: A Detailed Cost and Market

iebpharmacy1

Osimertinib 80 mg is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) widely used in the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). Known globally under the brand name Tagrisso, osimertinib has transformed lung cancer management by offering targeted efficacy with improved tolerability. In China, where lung cancer prevalence is among the highest in the world, access, pricing, and reimbursement of osimertinib 80 mg play a crucial role in patient outcomes.

This article explores the price of Osimertinib 80 mg price in China, key factors influencing its cost, the role of national insurance policies, availability of generics, and how China compares with global markets.

Overview of Osimertinib 80 mg

Osimertinib is specifically designed to target both common EGFR mutations (Exon 19 deletion and L858R substitution) as well as the resistant T790M mutation. It is commonly prescribed as:

First-line therapy for EGFR-mutated NSCLC

Second-line treatment after resistance to earlier EGFR inhibitors

The standard adult dosage is 80 mg once daily, taken orally, making long-term affordability a critical consideration for patients.

Osimertinib 80 mg Price in China

In China, the price of osimertinib 80 mg is significantly lower than in many Western countries, primarily due to government intervention, centralized drug procurement, and inclusion in national insurance programs.

Typical Price Range

Original brand (Tagrisso 80 mg):
The monthly cost in China is typically several thousand Chinese Yuan, markedly reduced compared to its initial launch price.

With national insurance reimbursement:
Patients may pay only a fraction of the listed price, depending on regional reimbursement policies.

Generic versions:
Locally manufactured generics are available at substantially lower prices, often costing 30–60% less than the branded drug.

Overall, China is one of the most affordable markets globally for osimertinib when insurance coverage is applied.

Impact of National Reimbursement Drug List (NRDL)

One of the most important reasons for the reduced price of osimertinib in China is its inclusion in the National Reimbursement Drug List (NRDL).

Key Benefits of NRDL Inclusion

Government-negotiated pricing with manufacturers

Significant reduction in out-of-pocket expenses

Increased access for patients in public hospitals

Standardized pricing across provinces

Following NRDL negotiations, the price of osimertinib dropped dramatically, making long-term treatment more sustainable for Chinese patients.

Role of Centralized Volume-Based Procurement

China’s Volume-Based Procurement (VBP) system also contributes to lower drug prices. Under this model:

Pharmaceutical companies agree to supply large quantities

In exchange, they offer steep price reductions

Hospitals prioritize centrally procured drugs

Although osimertinib is a high-value oncology medicine, procurement negotiations have helped stabilize pricing and prevent excessive mark-ups.

Availability of Generic Osimertinib in China

China has a robust pharmaceutical manufacturing sector, and generic osimertinib 80 mg is produced by several domestic companies.

Advantages of Chinese Generics

Approved by the National Medical Products Administration (NMPA)

Bioequivalent to the original drug

Significantly lower cost

Widely available in oncology hospitals and pharmacies

For uninsured patients or those seeking more affordable options, generics offer a practical alternative without compromising therapeutic effectiveness.

Comparison with Global Osimertinib Prices

When compared internationally, China’s osimertinib pricing is highly competitive:

Region        Relative Price Level
United States        Very high
Europe        High to moderate
Japan        High
China        Low to moderate
India (generics)        Very low

China stands out for offering brand-name osimertinib at prices close to or even lower than generics in some regions, especially after insurance reimbursement.

Factors Influencing Osimertinib Price in China

Several factors determine the final price paid by patients:

Insurance coverage status

Hospital tier and location

Brand vs generic selection

Provincial reimbursement policies

Supply contracts and procurement cycles

Urban tertiary hospitals often provide the most consistent access and pricing transparency.

Affordability and Patient Access

Lower pricing has significantly improved patient adherence to treatment. Since osimertinib is often used for extended periods:

Reduced cost helps prevent treatment interruption

Financial toxicity is minimized

Survival outcomes improve with continuous therapy

China’s pricing reforms have become a global reference model for balancing innovation with affordability in oncology care.

Conclusion

The price of osimertinib 80 mg in China reflects a successful combination of government negotiation, insurance inclusion, and domestic pharmaceutical production. Compared to global markets, Chinese patients benefit from substantially lower costs, especially through the NRDL reimbursement system and access to high-quality generics.

For lung cancer patients requiring long-term EGFR-targeted therapy, China offers one of the most accessible environments for osimertinib treatment today. As healthcare reforms continue, affordability and availability are expected to improve even further—bringing advanced cancer care within reach for more patients.